“We can now more freely serve our growing customer base in the in vitro diagnostics market and execute on our mission of improving quality of life by advancing a global understanding of disease,” says Charles Mamrak, CEO, SeraCare.
Financial terms of the transaction were not disclosed.
SeraCare has reorganized into three market-based commercial business units: IVD research, IVD processing, and clinical laboratory.
The company now has a complete senior management team, with five new key executives to lead its commercial business units and operations, R&D, and quality organizations.
“Our industry is entering a period of great change as new diagnostics technologies enable an unprecedented level of personalized medicine,” Mamrak says. “Our customers need our help in turning these changes into business opportunities. Allowing our customer-facing personnel to focus on a single, key market will make it easier for them to anticipate and meet these customers’ needs.”
The new executive team is comprised of Russell Garlick, PhD, chief scientific officer; Cheri Walker, PhD, chief commercial officer; Ann McCormick, COO; Joe Kozma, vice president of IVD process solutions; and Lisa Alexander, vice president, quality and regulatory.
Walker will act as the head of the IVD research and clinical laboratory business units and oversee corporate development activities.